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Background: Implantable left ventricular assist devices are common as a
bridge to transplantation but are just reaching their goal as an alternative
to transplantation. Methods: From December 1991 until December 1996, 97
left ventricular assist devices were implanted as a bridge to transplanta-
tion, one as an alternative to transplantation, and two as a bridge to
recovery. Included were 64 pneumatic devices and 36 electric devices. Most
patients (69%) had ischemic cardiomyopathy and most (53%) had had
previous cardiac surgery. Preoperative circulatory support (extracorporeal
membrane oxygenation) was used in 25. Results: Perioperative insertion of
a right ventricular assist device was unusual (11%). The mean duration of
support with a left ventricular assist device (bridge to transplantation) was
70 6 41 days (up to 206 days). Survival to transplantation was 76%. Cause
of death included multiple organ failure (n 5 13), perioperative stroke (n 5
5), device failure (n 5 5), and controller disconnect (n 5 1). Significant risk
factors for death included (1) preoperative need for ventilator or extracor-
poreal membrane oxygenation, (2) elevated blood urea nitrogen, creatinine,
or bilirubin, and (3) low pulmonary artery pressures. Risks after insertion
of the left ventricular assist device were reoperation for bleeding, support
with a right ventricular assist device, dialysis, or device failure. Cata-
strophic failure of the device occurred 14 times in 12 patients and was
treated by emergency pump exchange in six instances. Only two device-
related thromboembolic episodes were detected. Positive blood cultures
were found in 59% of patients, driveline infection in 28%, and pump
infection in 11%. Conclusions: The HeartMate device provided excellent
hemodynamic support with low device-related thromboembolic events.
Infection and reliability of the device contributed to the high cost of
therapy. These areas need to be improved for the left ventricular assist
device to attain its goal as a viable alternative to transplantation. (J Thorac
Cardiovasc Surg 1998;115:904-12)
Mechanical circulatory support technology hasundergone a rapidly accelerating pace of mat-
uration. In the 1970s the use of external left ventric-
ular assist devices (LVADs) for postcardiotomy
support were remarkable for the occasional survi-
vor. In the 1980s permanent implants of the total
artificial heart were introduced, only to be aban-
doned in favor of temporary support as a bridge to
transplantation. The 1990s have seen a much faster
rate of clinical and technologic development, with
the introduction of portable battery-powered
LVADs for bridge to transplantation, permanent
LVADs as an alternative to transplantation or med-
ical therapy, or long-term LVAD support until
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sufficient cardiac recovery has occurred to allow
LVAD weaning and removal (bridge to recovery).1-4
Our experience with the HeartMate LVAD
(Thermo Cardiosystems, Inc., Woburn, Mass.) be-
gan in December 1991 with the pneumatic system
used for inpatient bridge to transplantation. By 1996
all Cleveland Clinic implants had been converted to
the portable electric LVAD system for use as out-
patient bridge to transplantation, as a bridge to
recovery, or for permanent implantation as part of
the REMATCH protocol (Randomized Evaluation
of Mechanical Assistance for the Treatment of Con-
gestive Heart Failure).5, 6 The purpose of this report
is twofold: to review the rapid changes in technology
and concepts and, more important, to objectively
analyze the results in light of use of the LVAD for
extended support as a bridge to recovery or perma-
nent implant.
Patients and methods
The mean age of the patients was 53 6 9 years (range
27 to 70 years), and 86% were male. Ischemic cardiomy-
opathy predominated (70%), and only 25% had idiopathic
dilated cardiomyopathy. Most patients (53%) had had
previous cardiac surgery. Although we endorse the con-
cept of early implantation of LVADs before the onset of
irreversible other organ failure, in reality this was rarely
possible. This may reflect a large number of outside
referrals or admissions with near moribund heart failure.
Circulatory support consisting of intraaortic balloon
pumps (IABPs) was present before the operation in 84%,
heparin-coated extracorporeal membrane oxygenation
(ECMO) in 25%, and one patient was transferred while
being supported with the Abiomed biventricular assist
device (Abiomed, Inc., Danvers, Mass.). Sixty-two pa-
tients were supported with ventilators because of pulmo-
nary edema or recent cardiac arrest. The mean cardiac
index was 1.64 6 0.30 L/min per square meter, with a left
atrial pressure of 25 6 7 mm Hg, pulmonary artery
diastolic pressure of 29 6 9 mm Hg, right atrial pressure
of 20 6 7 mm Hg, and pulmonary vascular resistance of
4.4 6 2.6 Wood units. Preoperative information used to
create a screening scale as reported by Oz and associates7
(and including 23 of our earliest patients) was collected
and analyzed.
All operations were performed on cardiopulmonary
bypass with the use of antegrade and retrograde cold
blood cardioplegia. The inflow cannula was inserted into
the left ventricular apex and secured with interrupted
pledget-supported sutures. The outflow graft was anasto-
Fig. 1. A, Patients supported by the pneumatic HeartMate LVAD were inpatients while awaiting
transplantation but were ambulating and exercising. B, Patients supported by the vented-electric
HeartMate LVAD could be discharged and resumed near-normal activities. This patient remodeled a
garage during LVAD support. Note the portable batteries powering the LVAD on his waist.
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mosed to the right side of the aorta at an oblique angle
that directed the graft under the right side of the sternum.
This was also performed during the single crossclamp
period. Care was taken to preserve patent coronary artery
bypass grafts. The LVAD was placed in the abdomen in
our first patient but preferentially in the abdominal wall
pocket in successive patients, as described.8 More re-
cently, we modified that technique so that the pump was
placed under the posterior rectus sheath (and just above
the peritoneum) to minimize contact of the pump with the
raw surface of the posterior part of the rectus muscle and
thereby decrease bleeding from the muscle. In additional
efforts to decrease perioperative bleeding, aprotinin was
administered to the last 93 consecutive patients, 2 units of
fresh frozen plasma was used to prime the cardiopulmo-
nary bypass circuit, and vitamin K was given before the
operation and for 3 days after the operation because an
earlier study documented that before LVAD insertion
patients have reduced levels of vitamin K–dependent
coagulation factors.9 A hemoconcentrator was used dur-
ing cardiopulmonary bypass to reduce fluid overload.
Our surgical techniques frequently had to be adapted to
the disease that we encountered and to the previous
cardiac operation. For patients with implantable cardio-
verter-defibrillator (ICD) patches and leads outside the
heart, we removed the foreign materials and ICD gener-
ator. For three patients with transvenous ICD systems, we
left the ICD and placed the LVAD pump within the
abdomen so that the LVAD pump and ICD generator
would not both be in the abdominal wall.
For patients with previous mechanical aortic (n 5 3) or
mitral (n 5 2) valve prostheses, the valve was rereplaced
with a tissue valve. The logic was that the tissue valve was
less likely to cause thrombosis. Left ventricular aneurysms
(n 5 4) were partially decalcified, excised, and thrombus
was carefully removed. The large ventriculectomy was
plicated around the inflow cannula with multiple inter-
rupted sutures. Patients with any angina underwent coro-
nary artery bypass to nonoccluded vessels with greater
than 50% stenosis, especially if the right coronary artery
was involved.
Ideally, the transplant operation began 2 hours before
anticipated return of the donor heart. Initially, we exposed
a femoral artery before sternotomy because the dense
adhesions encountered (many patients were undergoing
their third cardiac operation or more) made reentry
dangerous. We rarely do this now (the femoral incision
heals poorly after transplant operations); instead we ex-
pose the outflow graft in the pocket for emergency
cannulation before resternotomy. Because the outflow
graft was placed under the right side of the sternum, it was
never entered during resternotomy.
After LVAD implantation, patients were given inotro-
pic agents as needed for right ventricular function. Nitric
oxide was never used because it was not available in our
institution. Alprostadil (prostaglandin E1) was given oc-
casionally early in our experience but was abandoned
because of limited effectiveness on pulmonary pressures
and the side effect of decreased systemic blood pressure.
Amrinone became routine for patients with right ventric-
ular dysfunction. Also, we adjusted LVAD flow down to
approximately 4 L to decrease blood return (and work-
load) to the right side of the heart. Care was taken to
avoid overdistention of the right ventricle (excessive vol-
ume transfusion) and to avoid hypoxemia and acidosis.
Pressure-controlled ventilation was standard.
Only aspirin (325 mg/day) was used for LVAD antico-
agulation. In patients with gastritis or other bleeding
disorders, aspirin was withheld or stopped. Vancomycin
was given during the operation, and other antibiotics were
given as directed by the infectious disease consulting
service.
Evolution of HeartMate LVAD. The HeartMate LVAD
has been described extensively in previous reports.1, 6 In
brief, pump inflow was from a cannula inserted into the
left ventricular apex, the pump was in the patient’s left
upper quadrant (in the abdominal wall, or intraperitone-
al), and pump outflow returned blood to the ascending
aorta approximately 3 cm distal to the aortic valve.
Blood-contacting surfaces are textured to promote the
formation of a pseudo-neointima, which contributes to the
low device-related thromboembolic event rates with this
device.10
Our initial experience (64 patients) was with the pneu-
matic air-driven system (1000 IP). Patients were tethered
to the portable air-driven console but were mobile and
could wander through the hospital and the hospital
grounds and exercise on a treadmill (Fig. 1, A). Logistics
of transporting the console, however, required that the
patient be maintained in the hospital until transplanta-
Table I. Thirty variables analyzed for risk factors
for death while on LVAD support
Preimplantation risk factors
Age
Sex
Diagnosis
Body surface area
Era (first 50 vs second 50 implants)
Ventilator
ECMO
IABP
Cardiac index
Pulmonary artery pressures (systolic/mean/diastolic)
Transpulmonary gradient
Pulmonary vascular resistance
Left atrial pressure
Right atrial pressure
Right ventricular ejection fraction
Total bilirubin
Creatinine
Blood urea nitrogen
Aspartate aminotransferase
Hematocrit
Operative and postoperative risk factors
Type of device (pneumatic vs electric)
RVAD
Reoperation for bleeding
Dialysis
Device infection
Device failure
Duration of support
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tion. A newer, smaller, portable driver for the pneumatic
system exists, but we have very limited clinical experience
with this system.
In 1993 we began to use the vented-electric HeartMate
LVAD, which contained the same blood-contacting sur-
faces and connections to the heart but was actuated
differently and was powered by portable batteries. The
initial vented-electric implants had a “two-lead” system
with separate percutaneous lines for power and external
venting. After further experience this became a “single-
lead” system with a single percutaneous driveline that
contained both the power cable and vent. Eventually the
single-lead system was moved so that it arose from the left
side of the pump, which allowed the surgeon to make a
long subcutaneous tunnel with the driveline, which could
exit from the patient’s right flank, and frequently leave 10
inches or greater of driveline within the subcutaneous
tissue. The hope is that the long tunnel will help resist
pocket infections. There have been many continuous
ongoing refinements of both the pneumatic and electric
systems to facilitate implantation and patient care and to
respond to device failures.
In 1995 we made the transition from pneumatic (1000
IP) implants to exclusively vented-electric implants. In our
opinion, the goal of permanent implants, or prolonged
implants allowing for bridge to recovery, will best be
accomplished using the portable electric systems. Through
a graduated series of steps, the Food and Drug Adminis-
tration (FDA) now allows patients supported by the
vented-electric device to be discharged before transplan-
tation (Fig. l, B). The net effect of all of these evolutions
in device design was that we progressed from inpatient
bridge to transplantation with air-driven systems to out-
patient support with portable, battery-powered devices for
a variety of destinations other than just bridge to trans-
plantation.
Statistical analysis. Results are reported as percent-
ages or means 6 standard deviation as appropriate.
Univariately, a x2 test or Fisher’s exact test was used to
compare the incidence of death in various groups. A
Wilcoxon rank sum test was used to compare the value of
continuous factors by death. The factors that were at least
marginally significant (p , 0.20) by univariate analysis
were included in a stepwise multivariable logistic regres-
sion model. The first model tested all these factors after
adjusting for the duration of support (forcing and keeping
duration of support in the model). The second model
included only the variables known at the time of implan-
tation (still adjusting for duration of support).
Results
Seventy-four of the 97 patients undergoing bridge
to transplantation (76%) survived until transplanta-
tion. Mean length of support was 70 6 41 days (up
to 206 days). Thirty preoperative or perioperative
variables were studied (Table I) to determine risk
factors for death. As expected, the duration of
support was less for the patients who died before
transplantation (35 vs 81 days; p , 0.001). Many
patients died early of progressive multiple organ
failure. Univariate risk factors for death before
transplantation (Table II) included preoperative
ECMO, ventilator requirement, low pulmonary ar-
tery pressures, and elevation of bilirubin (4.5 vs 2.6
mg/dl), blood urea nitrogen (49 vs 34 mg/dl), and
creatinine (2.0 vs 1.5 mg/dl) concentrations. Postop-
erative risks included need for support with a right
ventricular assist device (RVAD), reoperation for
bleeding, dialysis, and device failure. Important
univariate factors that were not found to be risk
factors for death included device type, diagnosis, era
(first 50 implants vs second 50 implants), need for
preoperative IABP, infection while on LVAD sup-
port, age, cardiac index, transpulmonary gradient,
pulmonary vascular resistance, right ventricular
ejection fraction, and right atrial pressure. By mul-
tivariable logistic regression (Table III), after ad-
justing for duration of support, risk factors for death
included postoperative dialysis (p 5 0.02, odds ratio
8.1 ), device failure (p 5 0.0006, odds ratio 29.1),
and requirement for an RVAD (p 5 0.09, odds ratio
6.2). When we analyzed only the variables that were
known before implantation, preoperative ECMO
(p 5 0.08, odds ratio 3.6) and creatinine (p 5 0.05,
odds ratio 2.4) were at least marginally significant.
We then analyzed our patients according to the
Table II. Significant or borderline univariate risk
factors for death
Risk factor Risk p Value
Preoperative
Ventilator use (% deaths) 33% versus 8% p 5 0.006
ECMO use (% deaths) 48% versus 16% p 5 0.003
Total bilirubin (mg/dl)
(median)
2.20 versus 1.4 p 5 0.01
Blood urea nitrogen (mg/
dl) (median)
46.0 versus 28.0 p 5 0.03
Creatinine (mg/dl)
(median)
1.8 versus 1.4 p 5 0.04
Pulmonary artery pressure,
mean (mm Hg)
(median)
31.5 versus 38.0 p 5 0.04
Pulmonary artery pressure,
systolic (mm Hg)
(median)
41.5 versus 50.0 p 5 0.06
Pulmonary artery pressure,
diastolic (mm Hg)
(median)
24.5 versus 29.0 p 5 0.08
Operative and postoperative
RVAD use (% deaths) 73% versus 18% p 5 0.0004
Need for dialysis
(% deaths)
63% versus 14% p 5 0.0004
Device failure (% deaths) 50% versus 20% p 5 0.03
Duration of support (days)
(median)
15 versus 78 p 5 0.0001
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screening scale created to identify patients at high
risk for death before discharge from the intensive
care unit (ICU) after HeartMate LVAD implanta-
tion.7 Failure in this article was defined as death
after LVAD implantation but before discharge from
the ICU, and the series included our initial 23
patients. This definition of failure applied in 16 of
our 97 patients (16.5%). In our 97 patients mechan-
ical ventilation was a risk factor for failure (22% vs
5.6%; p 5 0.03), urine output less than 30 ml per
hour was a borderline risk factor (36% vs 13%; p 5
0.07), and a total score greater than 5 was significant
(24% vs 6%; p 5 0.02). However, when analyzing
the 64 patients operated on since the initial group
were used to create the scale, we no longer can
identify any significant, or borderline significant, risk
factors (mechanical ventilation 16% vs 4%; p 5
0.22; low urine output 17% vs 10%; p 5 0.52; score
greater than 5, 13% vs 3%; p 5 0.29).
The causes of death before transplantation were
multiple organ failure with sepsis (n 5 13), periop-
erative intracranial bleeding and stroke (n 5 5),
complications from device failure (n 5 5), and
disconnection of the electric controller, which oc-
curred in one patient who was found dead at home
(by later analysis the device and controller appeared
to function well). The reason the patient discon-
nected the controller (and stopped pump function)
is unknown. Two patients had bridge to recovery.
One patient had dilated cardiomyopathy and had
been on device support for 3 months with persistent
positive blood cultures and a pump infection. He
underwent removal of the LVAD along with partial
left ventriculectomy (Batista procedure).5 The pa-
tient returned to New York Heart Association func-
tional class II but died at an outside hospital from
the rapid return of heart failure 7 months after
device removal. The other patient had had partial
left ventriculectomy and received the HeartMate
LVAD days later because of fever, hypotension, and
borderline cardiac function. The patient’s cardiac
function improved during HeartMate support and
he underwent device removal after 86 days. The
patient is alive (functional class II) 14 months after
device removal. The one patient with a permanent
implant did well initially but died of device failure
after 8 months, as has been reported.4
Perioperative morbidity was not uncommon in
these seriously ill patients. Perioperative reopera-
tion for bleeding was required in 21%. The need for
perioperative RVAD support was low, only 11%.
Three patients had severe right ventricular dysfunc-
tion with low flow, but this was thought to be due to
the effects of hypoxemia on the pulmonary vascular
resistance. These patients were treated with veno-
venous ECMO (returning oxygenated blood to the
right atrium), and all showed an immediate im-
provement in right ventricular function and were
easily weaned from venovenous ECMO after diure-
sis improved their pulmonary edema.
Device-related thromboemboli were remarkably
uncommon despite minimal or no anticoagulation.
Only two patients had transient ischemic attacks.
Other neurologic events were seen in the immediate
postoperative period and were thought to be related
to preoperative or intraoperative events (prolonged
cardiac arrest, intracranial bleeding from heparin,
embolus from intraventricular thrombus). There
were no air emboli during device insertion. At the
time of device explantation, while waiting for the
donor heart, one patient had an air embolus origi-
nating from the LVAD inflow, and she died from
cerebral anoxia after transplantation.
Positive blood cultures were common and were
detected in 59% of patients during support. All
patients had been in ICUs before LVAD insertion,
and all had multiple deep lines that were frequently
the source of infection. Clinical driveline infection
occurred in 28% of patients and clinical pump
infection in 11% of patients (fever, positive blood
cultures, tenderness over the device, and positive
cultures from the device). We never denied trans-
plantation to patients solely because of device infec-
tion or clinical driveline infection. In fact, that was
considered an indication for urgent transplantation,
sometimes with a marginal donor or a donor who
was positive for hepatitis C virus. At the time of
transplantation, the LVAD pocket was opened first,
the infected area was copiously irrigated with saline
and antibiotic solution, and then the remainder of
Table III. Results of multivariable logistic regression
Factor Odds ratio 95% CI p Value
Considering preoperative and postoperative factors
(adjusted for duration of support)
Postop. dialysis 8.1 1.3-50 0.02
Device failure 29.1 4.2-200 0.0006
Creatinine 2.7 0.95-2.0 0.06
RVAD requirement 6.2 0.75-50.6 0.09
Considering only baseline factors
(adjusted for duration of support)
ECMO 3.6 0.85-14.8 0.08
Creatinine 2.4 0.98-5.65 0.05
CI, Confidence interval.
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the transplant operation was completed. Only one
patient had a low-grade wound infection in the
pump pocket necessitating debridement after trans-
plantation. There were no posttransplantation
deaths related to infection.
Twelve patients had catastrophic device-related
events, and two patients had more than one event.
Fracture of the internal tubing of the pneumatic
driveline caused air leaks in three patients, resulting
in low flow. One patient died, and two patients
required emergency reoperation for pump replace-
ment.11 Blood leak from the inflow valved conduit
(Fig. 2) caused major hemorrhage in six pa-
tients.12, 13 One patient had had previous pump
replacement for internal pneumatic fracture. This
patient died of sepsis and multisystem failure shortly
after device replacement. Another patient required
pump replacement for inflow bleeding, recovered,
but had a second bleeding event. Only the inflow
conduit was replaced during the second bleeding
episode. The patient was in moribund condition
hours after this operation, underwent a desperate
heart transplant operation, and died the next day of
multisystem failure. Inflow conduit leaks occurred in
four other patients, and one patient required pump
replacement. Two patients had intermittent bleed-
ing from the percutaneous driveline site necessitat-
ing increasing blood transfusions. Urgent heart
transplantations using marginal donors were per-
formed in both, and erosions in the inflow conduit
were noted at transplantation. The fourth patient
had episodes of sepsis before the inflow valve hem-
orrhage and was thought to be too ill to undergo
emergency pump replacement. This patient died of
bleeding. Another patient was returned to the op-
erating room to evaluate fluid accumulation in the
pump pocket and bleeding from the driveline site.
At surgery we found the outflow valved conduit was
disconnected from the graft, and he required rapid
cannulation for cardiopulmonary bypass and recon-
nection of the outflow valve site. This patient un-
derwent transplantation within 24 hours and recov-
ered. Another patient became hypotensive after
being turned, and he was immediately returned to
the operating room. The inflow cannula had pulled
out of the sleeve securing it into the left ventricle,
and the patient bled to death. In another patient
electrical malfunction resulted in emergency reop-
eration because the pump stopped (the back-up
pneumatic actuation failed also). We exchanged the
vented-electric system for a pneumatic device and
he underwent successful transplantation later. Pump
failure of the electric system occurred in the patient
on permanent support and the back-up system did
not function. The patient died.4
In summary, 14 major device-related events oc-
curred in 12 patients, and six of these patients died.
Some of these mechanisms of device failures have
already been reported in the literature.2, 4, 11-13 Most
important, the major causes of device failure (inflow
conduit bleeding, percutaneous driveline fracture,
and failure of the electric system) had causes that
were identified, analyzed, and corrected in newer
versions of the device. The failures in our devices
were with some of the very earliest implants of the
systems, and new techniques may help predict prob-
lems before device failure.14-16
Hospital charges were available since 1993 in 67
patients (43 with pneumatic devices; 24 with vented-
electric devices). The mean hospital charge (6
standard deviation) from the time of implantation
until the time of transplantation or death was
$244,000 6 $100,000 total: $257,000 6 $106,000 for
the pneumatic device and $220,000 6 $87,000 for
the electric device. There was no statistically signif-
icant difference in charges by type of device (p 5
0.20).
Of the 35 patients undergoing bridge to trans-
plantation with an electric device, 26 were on sup-
port for greater than 30 days and therefore met the
earliest FDA criteria for potential hospital release.
Twenty-three patients met echocardiographic crite-
ria (aortic valve opened intermittently when the
Fig. 2. A, Patient required an emergency operation for
sudden massive bleeding months after LVAD insertion.
An erosion of the inflow cannula (indicated by forceps)
was identified and successfully managed by LVAD re-
placement.
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pump rate was decreased to a fixed rate of 50
beats/min), 22 patients had a companion available,
and 20 patients were in medically stable condition.
Eighteen patients entered into the protocol with day
trips. Twelve of 18 took a 3-day pass, and 7 of the 18
were discharged to their homes. Failure to progress
to discharge was related to development of blood-
stream infections (n 5 6), device malfunction (n 5
l), ventricular fibrillation (n 5 1), and insufficient
rehabilitation (n 5 1). Two patients were discharged
but withdrew from the release protocol and were
returned to the hospital to wait for transplantation
because of frequent changes of the controller (n 5 l)
and perceived excessive burden on the companion
(n 5 1).
Actuarial survival during LVAD support is illus-
trated in Fig. 3. This figure shows that the risk of
death is not just early failures in the ICU but
continues because of the unpredictable occurrence
of device failures. Actuarial survival of the 74 pa-
tients after transplantation showed a 1-year survival
of 90% 6 3.5% and a 4-year survival of 80% 6 7.2%
(mean 6 standard error).
Discussion
The rapid evolution in LVAD technology points
to a promising future. The devices are hemodynam-
ically effective, with a low need for perioperative
RVAD support and an extremely low risk of device-
related thromboemboli with the HeartMate device.
The portable electric system allows the patients
greater mobility and the expectation for hospital
discharge. There are still problems to be addressed
and solved, but the LVADs are already effective and
much safer than the alternative (continued medical
therapy), which in this end-stage patient population
has a low chance of success.
The proper timing for LVAD insertion is still
controversial. It is intuitively obvious that early
LVAD implants will yield a higher chance of suc-
cessful bridge to transplantation than when the
patient is moribund. Nevertheless, the cost of bridge
to transplantation is high (average hospital charge
$244,000), and it does expose patients to complica-
tions unique to mechanical circulatory support (in-
fection, device failure, air emboli). Therefore we
have waited until decompensation begins before
proceeding to LVAD implant. We may carefully
watch a patient without LVAD implantation while
waiting for a “marginal” donor (e.g., hepatitis C
virus positive, older donor with normal coronary
angiography). Several patients who have been
scheduled for LVAD implantation underwent trans-
plantation the night before with marginal donor
organs.
The dilemma is what to do with patients who
are already in severe shock, frequently with im-
pending multiple organ failure. These patients
may be admitted after acute myocardial infarction
(e.g., left main occlusion), may be transferred
from outside institutions, or their condition may
have deteriorated after recent cardiac surgery.
This was more typical of our patient population,
such that 83% were on IABP support and 25%
were in such severe shock that they required
ECMO for circulatory support before LVAD in-
sertion. The screening scale originally proposed
would indicate that these patients are at very high
risk for early failure after LVAD insertion.7 The
decision then can be made to not insert an LVAD;
however, the outcome will almost invariably be
fatal for these patients. Alternatively, we have
proceeded with LVAD insertion, understanding
that the chances of success may be reduced. For
some patients ECMO support was used to stabi-
lize other organs that were failing (e.g., renal and
hepatic function, which were predictors of mor-
tality in our experience) and to determine that the
patient was a transplant candidate (for patients
who have not previously been assessed). With
increased experience we became more aggressive,
using ECMO before LVAD implantation for
these moribund patients, and this may explain why
the screening scale was not able to accurately
predict failures after LVAD insertion in our more
recent experience.17, 18 Survival to transplantation
Fig. 3. Actuarial survival on LVAD support demon-
strates early mortality, usually from multiple organ failure
or perioperative strokes. Later mortality was usually from
device failure.
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for our 25 patients supported by ECMO before
LVAD insertion was 68%.
Although most of our experience has been bridge
to transplantation, there are evolving new uses for
implantable LVADs: permanent implants or long-
term bridge to recovery.2-5 Experiences with these
new uses are still early and anecdotal but indicate
the rapid introduction of concepts in this field. Also,
in the past year we have aggressively used LVAD
“back-up” for high-risk conventional operations
(coronary artery bypass, valve surgery, aneurysmec-
tomy, or partial left ventriculectomy) as alternatives
to transplantation. If the conventional operation
fails, then the patient has already been approved as
a transplant candidate and can be expeditiously
placed on LVAD support as a bridge to transplan-
tation.
The ultimate goal of LVAD technology must be
for long-term use, either as a bridge to recovery or
for permanent implants. Bridge to transplantation
is an expensive way to rearrange which patients
receive the scarce number of donors, and it does
not solve the huge deficit in donor organs. The
evolution in device technology has eliminated
many obstacles to permanent implants. However,
to successfully achieve this goal, in a cost-effective
manner, we must focus our efforts on solving the
remaining problems. Device durability and reli-
ability may become major issues as patients have
extended support. Fortunately, the complications
that we had with device failure can be addressed
and corrected. However, just like the first pace-
maker implants and heart valve implants, this
technology is still a “work in progress.” Further
refinements will be necessary. Infection, either
systemic via indwelling catheters or ascending via
the driveline, are another potential threat to
success of permanent implants. The true magni-
tude of the problem will not be apparent from the
bridge-to-transplantation experience because in-
fections can be suppressed until a donor becomes
available, or urgent transplantation can be per-
formed in the face of device infection. However,
for permanent implants, chronic infection will
decrease quality of life, increase cost of therapy,
and may require pump replacement(s) or device
explantation if cardiac improvement has occurred.
Finally, we need to do all that we can to expedite
approval of these devices. The epidemiology sug-
gests that every day, hundreds of patients die of
end-stage heart disease who may otherwise be can-
didates for mechanical circulatory support.19 Al-
though the devices are not yet perfected, they are
better than the alternative. In addition, only through
extensive clinical experience are we able to learn
about the shortcomings of mechanical circulatory
support and then make modifications and improve-
ments as needed. Delays in the process only cost
more patients their lives.
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Discussion
Dr. Walter P. Dembitsky (San Diego, Calif.). When you
compared the vented-electric devices and those with
pneumatic devices, you noted no significant changes in the
Nottingham quality of life profile. In our own experience,
discharge to home has had the most profound effect on
the quality of life profile. Were any of your patients with
the vented-electric device discharged to their homes?
Dr. Smedira. Our experience will mimic yours in that
patients who can leave the hospital and are free to go
home and return to their environment have a significant
improvement in their quality of life. Their hospital dis-
charge also improves the quality of life of their compan-
ions and families. The requirement for discharge to have
a companion and to be tethered either to the hospital or
to a facility close to the hospital is a significant strain for
all members involved with support.
Dr. Dembitsky. The way these implanted LVADs inte-
grate themselves into the patient is going to be increas-
ingly important. We have seen the late development of
aortic insufficiency in two patients. The cause, we believe,
is that the valve is obliged to continuously carry both
systolic and aortic pressure during LVAD ejection. There-
fore, we think that aortic insufficiency is due to the
dilatation at the sinotubular ridge. We now reinforce that
area with felt when we implant the pumps. Have you seen
any instances of late aortic insufficiency?
Dr. Smedira. We have not.
Dr. Dembitsky. The results of bridge to transplantation
after VAD implantation are excellent around the world,
but the results of bridge to recovery and the results of
using these devices as an alternative to transplant are
unknown. You are involved with the REMATCH trial. I
know you do not have enough experience to do anything
but speculate about bridge to recovery, but I would like to
hear what you think the results will be. Also, can you tell
us a little bit about the REMATCH trial?
Dr. Smedira. The REMATCH trial is currently involv-
ing three centers, the Cleveland Clinic, Texas Heart
Institute, and Columbia University, and will involve the
randomization of patients with end-stage congestive heart
failure to either permanent device therapy or medical
therapy. It appears that the criteria for inclusion will be
patients who are older or who have comorbidities that
exclude them from transplantation. To date, nine patients
have been randomized, five to the surgical arm and four to
the medical arm.
It is too early in the bridge-to-recovery program to
guess what the results will be. There are anecdotal expe-
riences: we have two, which I mentioned, Texas Heart has
a few, Columbia has a few, and there is a larger series
from the Berlin Heart Institute. We know that reverse
remodeling of the ventricle occurs with LVAD support.
The difficulty as I see it will be selecting the patients with
a dilated cardiomyopathy who will be best served with
temporary LVAD support and then explantation. Also,
issues of how long the patient can be supported with the
hope of ventricular recovery are still unknown. And after
removal of the LVAD, will the process return?
Dr. Vaughn A. Starnes (Los Angeles, Calif.). This is a
very effective, reliable pump. One of the issues that will
surface, however, is the biologic valve that is currently
used in this pump. If we are evaluating this device as an
alternative to transplantation, what are the considerations
about these valves? Will we simply exchange them? Will
we change the configuration of the pump, perhaps by
using a mechanical valve? Of course, doing that raises the
issue of anticoagulation. How are you addressing this
problem?
Dr. Smedira. That is a valid concern. The stresses on
the valves are quite high with the rate of pressure rise
generated by the pump. The use of mechanical valves in
the pump and the need for anticoagulation create a set of
problems that we will have to deal with. We need to look
at alternatives to the prosthetic valve, but right now we do
not have anything on the drawing board.
Dr. Edward D. Verrier (Seattle, Wash.). One of the
advantages of this device is that the biologic membrane
that lines the inner bladder causes an endothelialization;
the endothelialization also seems to dramatically increase
the preformed reactive antibodies. Almost all of these
patients have a marked increase in such reactive antibod-
ies. Has that affected your ability to then match them for
transplantation? Has your waiting time increased? What
would be an effective therapy to avoid that sensitization?
Dr. Smedira. We evaluated our experience with pre-
formed reactive antibodies and found no effect on our
ability to perform transplantation in these patients. How-
ever, a few patients that had extremely high preformed
reactive antibodies (901%) have been difficult to manage.
We found when we reviewed our experience that it is the
number of blood products that were transfused during the
support period, specifically platelets, that resulted in a
higher preformed reactive antibody score than those that
had fewer blood products. To avoid that, we have used
aprotinin routinely in all but our first patients and tried to
diminish the number of blood products that the patients
are receiving, especially platelets. For the patients who
have had elevated preformed reactive antibodies, we have
used both plasmapheresis and immunoglobulins to try to
reduce the antibodies. These methods have been generally
successful.
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